San Francisco, California, United States The venture was found in North America in United States. The main department of described VC is located in the San Francisco.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Kearny Venture Partners, startups are often financed by OrbiMed, Aisling Capital, Venture Investors. The meaningful sponsors for the fund in investment in the same round are Aisling Capital, F-Prime Capital, Venture Investors. In the next rounds fund is usually obtained by OrbiMed, New Enterprise Associates, F-Prime Capital.
Comparing to the other companies, this Kearny Venture Partners performs on 5 percentage points less the average number of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. Considering the real fund results, this VC is 12 percentage points less often commits exit comparing to other organizations. The important activity for fund was in 2013. The higher amount of exits for fund were in 2014.
This organization was formed by Caley Castelein. Besides them, we counted 2 critical employees of this fund in our database.
Among the most popular portfolio startups of the fund, we may highlight ViewRay, CVRx, Aerpio Pharmaceuticals. Among the most successful fund investment fields, there are Therapeutics, Health Care. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Aztec Venture Network | California, San Diego, United States |
| Celeridem Capital Management | Florida, Tampa, United States |
| Exponential Creativity Ventures | New York, New York, United States |
| Fidelium Group | Central, Central Region, Singapore |
| Four Score Capital | Boston, Massachusetts, United States |
| GGM Capital | Canton Luxembourg, Luxembourg, Münsbach |
| Gongyinglian Chanye Fazhan Jijin | China, Henan, Henan |
| Huiyu Ziben | China, Hubei, Wuhan |
| ICICI Lombard General Insurance | India, Maharashtra, Mumbai |
| JMP Securities | California, San Francisco, United States |
| Manbang Group | China, Guiyang, Guizhou |
| MSA Venture Partners | - |
| New Evolution Ventures (NeV) | California, Lafayette, United States |
| Pushtech Technologies | - |
| Saudi Aramco | Ash Sharqiyah, Dhahran, Saudi Arabia |
| Soros Economic Development Fund | New York, New York, United States |
| Stateline Angels | Illinois, Rockford, United States |
| Tnuva | Glil Yam, Israel, Tel Aviv |
| UBA Group | Lagos, Lagos, Nigeria |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cybin | $35M | 01 Jul 2020 | Ontario | ||
Aerpio Pharmaceuticals | $22M | 23 Apr 2014 | Cincinnati, Ohio, United States | ||
Aerpio Pharmaceuticals | $36M | 06 Nov 2013 | Cincinnati, Ohio, United States | ||
Boreal Genomics | $18M | 04 Oct 2013 | British Columbia | ||
Akebia Therapeutics | $41M | 04 Jun 2013 | Cambridge, Massachusetts, United States | ||
ViewRay | $45M | 13 Mar 2012 | Cleveland, Ohio, United States | ||
Akebia Therapeutics | $22M | 26 Apr 2011 | Cambridge, Massachusetts, United States | ||
NextWave Pharmaceuticals | $45M | 11 Jan 2011 | Cupertino, California, United States | ||
ViewRay | $20M | 25 Aug 2010 | Cleveland, Ohio, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cybin | $35M | 01 Jul 2020 | Ontario | ||
Aerpio Pharmaceuticals | $22M | 23 Apr 2014 | Cincinnati, Ohio, United States | ||
Aerpio Pharmaceuticals | $36M | 06 Nov 2013 | Cincinnati, Ohio, United States | ||
Boreal Genomics | $18M | 04 Oct 2013 | British Columbia | ||
Akebia Therapeutics | $41M | 04 Jun 2013 | Cambridge, Massachusetts, United States | ||
ViewRay | $45M | 13 Mar 2012 | Cleveland, Ohio, United States | ||
Akebia Therapeutics | $22M | 26 Apr 2011 | Cambridge, Massachusetts, United States | ||
NextWave Pharmaceuticals | $45M | 11 Jan 2011 | Cupertino, California, United States | ||
ViewRay | $20M | 25 Aug 2010 | Cleveland, Ohio, United States |
